AR076688A1 - Derivados de isoquinolin-1(2h)-ona - Google Patents
Derivados de isoquinolin-1(2h)-onaInfo
- Publication number
- AR076688A1 AR076688A1 ARP100101720A ARP100101720A AR076688A1 AR 076688 A1 AR076688 A1 AR 076688A1 AR P100101720 A ARP100101720 A AR P100101720A AR P100101720 A ARP100101720 A AR P100101720A AR 076688 A1 AR076688 A1 AR 076688A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- optionally substituted
- cycloalkyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 C3 -7- Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 abstract 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan derivados de isoquinolin-1(2H)-ona sustituidos que inhiben selectivamente la actividad de poli (ADP-ribosa) polimerasa PARP-1 con respecto a poli (ADP-ribosa) polimerasa PARP-2. Por lo tanto, los compuestos de la presente son utiles para tratar enfermedades tales como cáncer, enfermedades cardiovasculares, lesiones del sistema nervioso central y diferentes formas de inflamacion. La presente también proporciona métodos para preparar estos compuestos, composiciones farmacéuticas que comprenden estos compuestos, y métodos para tratar enfermedades utilizando composiciones farmacéuticas que comprenden estos compuestos. Un método de sondeo para la identificacion de compuestos capaces de unirse a varias proteínas PARP, y también las sondas usadas en ese método, son otros objetivos de la solicitud. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1): donde L es un grupo opcionalmente sustituido C2-6 alquilo lineal o ramificado, C3-7 cicloalquilo o, incluyendo el átomo de nitrogeno al cual está unido, un heterociclilo o heterociclil C1-6 alquilo opcionalmente sustituido; R y R1 son independientemente un átomo de hidrogeno, un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C3-7 cicloalquilo, heterociclilo, arilo, heteroarilo o COR5 o, tomados juntos con el átomo de nitrogeno al cual están unidos, forman un grupo heterociclilo o heteroarilo opcionalmente sustituido; R2 y R3 son independientemente un átomo de hidrogeno o de halogeno; un grupo ciano, nitro, NHCOR5, COR5, NR6R7, NR6COR5, OR8, SR8, SOR11, SO2R11, NHSOR11, NHSO2R11, R9R10N-C1-6 alquilo, R9O-C1-6 alquilo, o un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo, heterociclilo, arilo o heteroarilo; R4 es un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado. C3-7 cicloalquilo, C2-6 alquenilo, C2-6 alquinilo, arilo, aril C1-6 alquilo, aril C3-7 cicloalquilo, aril C2-6 alquenilo, aril C2-6 alquinilo, heterociclilo, heterociclil C1-6 alquilo, heterociclil C3-7 cicloalquilo, heterociclil C2-6 alquenilo, heterociclil C2-6 alquinilo, heteroarilo, heteroaril C1-6 alquilo, heteroaril C3-7 cicloalquilo, heteroaril C2-6 alquenilo, heteroaril C2-6 alquinilo; R5 es un átomo de hidrogeno o NR6R8, OR8, SR8, R9R10N-C1-6 alquilo, R9O- C1-6 alquilo, o un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo, heterociclilo, arilo o heteroarilo; R6 y R7 son independientemente un átomo de hidrogeno, un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo, R9R10N-C2-6 alquilo, R9O-C2-6 alquilo, heterociclilo, arilo o heteroarilo, o R6 y R7, tomados juntos con el átomo de nitrogeno al cual están unidos, pueden formar un grupo heterociclilo opcionalmente sustituido; R8 es hidrogeno o un grupo COR6, SOR11, SO2R11, R9R10N-C2-6 alquilo o R9O-C2-6 alquilo, o un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7-, cicloalquilo, heterociclilo, arilo o heteroarilo, donde R6 es como se definio más arriba; R9 y R10 son independientemente hidrogeno, COR5, o un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo, heterociclilo, arilo o heteroarilo, o R9 y R10, tomados juntos con el átomo de nitrogeno al cual están unidos, pueden formar un grupo heterociclilo opcionalmente sustituido, donde R5 es como se definio más arriba; R11 es un átomo de hidrogeno, NR6R7, OR8, R9R10N-C1-6 alquilo, R9O-C1-6 alquilo, o un grupo opcionalmente sustituido C1-6 alquilo lineal o ramificado, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo, heterociclilo, arilo o heteroarilo, donde R6, R7, R8, R9 y R10 son como se definio más arriba; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160869 | 2009-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076688A1 true AR076688A1 (es) | 2011-06-29 |
Family
ID=42372343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101720A AR076688A1 (es) | 2009-05-21 | 2010-05-18 | Derivados de isoquinolin-1(2h)-ona |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8592416B2 (es) |
| EP (1) | EP2432765B1 (es) |
| JP (1) | JP5731486B2 (es) |
| CN (1) | CN102438986B (es) |
| AR (1) | AR076688A1 (es) |
| AU (1) | AU2010251112B2 (es) |
| BR (1) | BRPI1011046B1 (es) |
| CA (1) | CA2762226C (es) |
| CL (1) | CL2011002925A1 (es) |
| DK (1) | DK2432765T3 (es) |
| EA (1) | EA023112B1 (es) |
| ES (1) | ES2568936T3 (es) |
| MX (1) | MX2011012187A (es) |
| TW (1) | TWI499418B (es) |
| WO (1) | WO2010133647A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| FR2956816B1 (fr) * | 2010-03-01 | 2012-05-18 | Univ Joseph Fourier | Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese |
| WO2013014038A1 (en) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| CA2856759A1 (en) * | 2011-11-25 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| LT2882714T (lt) | 2012-08-08 | 2020-03-10 | Merck Patent Gmbh | (azo-)izochinolinono dariniai |
| SG11201502120XA (en) | 2012-09-26 | 2015-04-29 | Merck Patent Gmbh | Quinazolinone derivatives as parp inhibitors |
| US9290454B2 (en) | 2012-10-01 | 2016-03-22 | Merck Sharp & Dohme Corp. | Substituted isoquinolines as CRTH2 receptor modulators |
| US10385018B2 (en) | 2012-10-26 | 2019-08-20 | Nerviano Medical Sciences S.R.L. | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
| AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| US11096909B2 (en) | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
| CN106083716B (zh) * | 2016-06-07 | 2018-10-30 | 温州医科大学仁济学院 | 一种3-芳基异喹啉化合物的制备方法 |
| US9891509B2 (en) | 2016-06-17 | 2018-02-13 | Mimono LLC | Projector holder |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| WO2019232223A1 (en) | 2018-05-30 | 2019-12-05 | University Of Notre Dame Du Lac | Hsp90 beta selective inhibitors |
| CN113549044B (zh) * | 2021-07-23 | 2024-01-23 | 中国药科大学 | 8-氮杂环取代色酮类衍生物及其制备方法与制药用途 |
| WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN121079090A (zh) | 2023-05-11 | 2025-12-05 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59116269A (ja) * | 1982-12-24 | 1984-07-05 | Nisshin Flour Milling Co Ltd | イソカルボスチリル誘導体 |
| JPS60237070A (ja) * | 1984-05-08 | 1985-11-25 | Nisshin Flour Milling Co Ltd | 光学活性イソカルボスチリル誘導体の製法 |
| DK0389995T3 (da) | 1989-03-28 | 1995-07-03 | Nisshin Flour Milling Co | Isoquinolinderivater til behandling af glaukom eller okular hypertension |
| JP3141051B2 (ja) | 1992-10-09 | 2001-03-05 | 日清製粉株式会社 | 抗動脈硬化剤 |
| SE9902268D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
| EP1397350B1 (en) * | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2004031171A1 (ja) * | 2002-10-01 | 2004-04-15 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| CA2507027C (en) * | 2002-11-22 | 2012-05-08 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2010
- 2010-05-17 TW TW099115650A patent/TWI499418B/zh active
- 2010-05-18 AR ARP100101720A patent/AR076688A1/es active IP Right Grant
- 2010-05-19 EP EP10723046.8A patent/EP2432765B1/en active Active
- 2010-05-19 ES ES10723046.8T patent/ES2568936T3/es active Active
- 2010-05-19 AU AU2010251112A patent/AU2010251112B2/en active Active
- 2010-05-19 MX MX2011012187A patent/MX2011012187A/es active IP Right Grant
- 2010-05-19 BR BRPI1011046-1A patent/BRPI1011046B1/pt active IP Right Grant
- 2010-05-19 US US13/320,969 patent/US8592416B2/en active Active
- 2010-05-19 DK DK10723046.8T patent/DK2432765T3/en active
- 2010-05-19 CA CA2762226A patent/CA2762226C/en active Active
- 2010-05-19 JP JP2012511282A patent/JP5731486B2/ja active Active
- 2010-05-19 CN CN201080021942.8A patent/CN102438986B/zh active Active
- 2010-05-19 WO PCT/EP2010/056921 patent/WO2010133647A1/en not_active Ceased
- 2010-05-19 EA EA201171448A patent/EA023112B1/ru not_active IP Right Cessation
-
2011
- 2011-11-18 CL CL2011002925A patent/CL2011002925A1/es unknown
-
2013
- 2013-10-23 US US14/061,100 patent/US8993594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2432765B1 (en) | 2016-03-02 |
| CN102438986A (zh) | 2012-05-02 |
| CA2762226C (en) | 2017-12-05 |
| EP2432765A1 (en) | 2012-03-28 |
| HK1166076A1 (en) | 2012-10-19 |
| CL2011002925A1 (es) | 2012-04-13 |
| EA201171448A1 (ru) | 2012-06-29 |
| WO2010133647A1 (en) | 2010-11-25 |
| US20120157454A1 (en) | 2012-06-21 |
| US20140045846A1 (en) | 2014-02-13 |
| TWI499418B (zh) | 2015-09-11 |
| CA2762226A1 (en) | 2010-11-25 |
| TW201043232A (en) | 2010-12-16 |
| US8993594B2 (en) | 2015-03-31 |
| CN102438986B (zh) | 2015-07-01 |
| AU2010251112A1 (en) | 2012-01-19 |
| US8592416B2 (en) | 2013-11-26 |
| BRPI1011046A2 (pt) | 2016-03-15 |
| DK2432765T3 (en) | 2016-04-25 |
| ES2568936T3 (es) | 2016-05-05 |
| MX2011012187A (es) | 2012-01-27 |
| EA023112B1 (ru) | 2016-04-29 |
| AU2010251112A2 (en) | 2012-02-02 |
| BRPI1011046B1 (pt) | 2020-02-27 |
| JP5731486B2 (ja) | 2015-06-10 |
| AU2010251112B2 (en) | 2015-11-12 |
| JP2012527428A (ja) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076688A1 (es) | Derivados de isoquinolin-1(2h)-ona | |
| AR077462A1 (es) | 3-oxo-2,3-dihidro-1h-isoindol-4-carboxamidas | |
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| CY1122218T1 (el) | Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| CU20130107A7 (es) | IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| AR077461A1 (es) | 1h-isoindoles con inhibicion selectiva de parp-1 | |
| ECSP109957A (es) | Derivados de pirimidinil-piridazinona. | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| CO6321286A2 (es) | Compuestos heterociclicos que contienen atomos de nitrogeno como unicos hetero atomos en el anillo en el sistema orto-condensado, y composiciones de los mismos, utiles como inhibidores de quinasa | |
| BR112018003634A8 (pt) | Processo para preparar um inibidor parp, formas cristalinas e usos destes | |
| ECSP10010356A (es) | Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| CR20140091A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| EA201170963A1 (ru) | Ингибиторы поли(адф-рибозо)полимеразы (parp) | |
| UY32531A (es) | Nuevos compuestos para el tratamiento de trastornos del snc | |
| AR067156A1 (es) | DERIVADOS DE TETRAHIDRO-2H-PIRIDO(4,3-B)INDOL-2-ILO, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA INHIBICION DE CATEPSINA K | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| CO6361910A2 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| EA201590820A1 (ru) | Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |